Use of enoxaparin in patients with chronic kidney disease: Safety considerations

Drug Safety

Volumn 30, Issue 11, 2007, Pages 991-994

  Brophy, Donald F ^a   Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enoxaparin sodium, adverse reactions; Enoxaparin sodium, therapeutic use; Kidney disorders; Renal impairment

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LEPIRUDIN;

ANTICOAGULATION; BLEEDING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HYPERKALEMIA; NOTE; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 35649003185     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730110-00001     Document Type: Note

References (17)

1. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30 (5): 579-89
2. United States Renal Data Systems (USRDS). 2006 annual data report: atlas of chronic kidney disease and end stage renal disease in the United States. Chapter 6: Morbidity and mortality. Am J Kidney Dis 2007; 49 (1 Suppl.): S130-46
3. Antman EM, McCabe CH, Gurfinkle EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100 (15): 1593-601
4. Cohen M, Demers C, Gurfinkle EP, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enox-aparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998; 82 (5B): 19L-24L
5. Buckley MM, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 44: 465-97
6. Noble S, Spencer CM. Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998; 56: 259-72
7. Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586-90
8. Lovenox® (enoxaparin sodium) [package insert]. Bridgewater (NJ): Sanofi-Aventis Pharmaceuticals, 2007 Jun
9. Brophy DF, Carr ME, Martin EJ, et al. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamics in patients receiving dialysis therapies. J Clin Pharmacol 2006; 465: 887-94
10. Brophy DF, Martin EJ, Gehr TWB, et al. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006; 4: 372-6
11. Gheno G, Cinetto L, Savarino C, et al. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol 2003; 59: 373-7
12. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84
13. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41
14. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856-63
15. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41: 8-14
16. Collet JP, Montalescot G, Choussat R, et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001; 80: 81-2
17. Hulot JS, Montalescot G, Lechat P, et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542-52